您的瀏覽器不支援JavaScript功能,若網頁功能無法正常使用時,請開啟瀏覽器JavaScript狀態!
Some images has been designed using resources from
Unsplash
&
Pixabay
&
Pexels
&
Freepik
and some icons from
Flaticon
跳到主要內容
跳到主要內容
:::
Home
Sitemap
International
Facebook
小
中
大
Branches
Suao
Yuanshan
Taoyuan
Hsinchu
Yu-Li
Fenglin
Taitung
Gan-Dau
Division of Plastic and Reconstructive Surgery, Taipei Veterans General Hospital
Worlds Best Hospitals
搜尋
Open main menu
Search
Search
About US
Previous and Present Chiefs
Service
Our Team
International Service
Aesthetic Medical Center
Burn Center
History of establishment
Team
Search
Search
本部簡介
簡介
歷任部主任
現任部主任
組織發展沿革
組織架構
醫學研究部現況
研究人員簡介
技術人員簡介
研究量能
臺北榮總CAR-T進展
臺北榮民總醫院學術研發成果
臺北榮總COVID防疫研究成果
NCI跨國合作實驗室介紹
行政單位
基礎研究科
轉譯研究科
臨床研究科
臨床試驗科
技術移轉組
臨床共同研究室
大數據中心
細胞治療創新研發中心
醫學科技大樓管理中心
醫療創新中心
研究單位
研究室
消化轉譯醫學研究室
腸胃腫瘤研究室
基因奈米醫學研究室
智慧醫療研究室
整合性腦功能研究室
癌症轉譯研究室
生物感測器實驗室
神經血管研究室
核磁共振研究室
精神疾病腦造影研究室
惡性肉瘤研究室
聽覺生理與基因醫學研究室
頭頸部腫瘤研究室
腫瘤分子調控研究室
系統生物醫學研究室
醣生物學研究室
細胞治療轉譯研究室
生物資訊研究室
系統生理研究室
轉錄基因體研究室
單細胞基因體研究室
毒物與代謝研究室
動物室
儀器服務及教育訓練課程
公用儀器教育訓練課程
公用儀器服務項目
流式細胞儀核心設施
顯微影像核心設施
代謝物定量核心設施
基因研究核心設施
細胞庫服務
致德樓「低溫冷凍櫃室」空間借用、遷入及遷出申請
公用儀器線上預約
醫學研究部其他公用儀器資源
研究諮詢
癌症基因體分析團隊全院合作推廣
研究倫理衝突輔導諮詢服務
論文原創性比對諮詢服務
醫學研究學術倫理專區
計畫申請
院內外計畫綜整
院內計畫
榮總臺灣聯合大學計畫
國科會計畫
榮總、三總與中研院合作研究計畫
榮總台大兩院合作研究計畫
臨床試驗計畫
論文獎勵
研究論文獎勵金申請
學術論文獎
研究倫理案件處理及審議要點
常用表單
門卡申請及退卡
實驗動物照護及使用委員會
生物安全會
修護室相關業務表單
創新獎
其它
Home
Sitemap
中文
International
BranchesHospital
SuaoHospital
YuanshanHospital
TaoyuanHospital
HsinchuHospital
YuLiHospital
FenglinHospital
TaitungHospital
GanDauHospital
Facebook
Home
Profile
:::
蕭樑材 (Hsiao Liang -Tsai)
Return Appointment
First Appointment
[Profile]
[Publications]
Wang HY, Yang CF, Chiou TJ, Yang SH, Gau JP, Yu YB, Chen PM, Hsu HC, Fung CP, Lin HY, Tzeng CH, Liu JH, Hsiao LT*. Risk of hemophagocytic lymphohistiocytosis in adults with fevers of unknown origin: the clinical utility of a new scoring system on early detection. Hematol Oncol. 2016 June 24 (in press). (*correspondence)
Hsiao LT, Wang HY, Yang CF, Chiou TJ, Gau JP, Yu YB, Liu HL, Chang WC, Chen PM, Tzeng CH, Chan YJ, Yang MH, Liu JH, Huang YH. Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients. Medicine (Baltimore) 2016; 95:e3064.
Yang SH, Hsiao LT*, Chiou TJ, Yang CF, Yu YB, Liu CY, Gau JP, Liu JH, Chen PM, Tzeng CH. Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma. J Chin Med Assoc 2015; 78:400-407.
Hsiao LT, Chiou TJ, Gau JP, Yang CF, Yu YB, Liu CY, Liu JH, Chen PM, Tzeng CH, Chan YJ, Yang MH, Huang YH. Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study. Medicine (Baltimore). 2015;94(32):e1321.
Hsiao LT, Tien HF, Kuo CY, Wu JH, Hou HA, Wang MC, Liu CY, Chen PM, Chiou TJ. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Hematol Oncol. 2015;33(4):136-44
Wang HY, Yang CF, Chiou TJ, Yang SH, Gau JP, Yu YB, Liu CY, Liu JH, Chen PM, Hsu HC, Fung CP, Tzeng CH, Hsiao LT*. A "bone marrow score" for predicting hematological disease in immunocompetent patients with fevers of unknown origin. Medicine (Baltimore). 2014;93(27):e243.
Hsiao LT*, Chung FP, Chiou TJ, Chen PM, Tzeng CH. The limitations of extracorporeal membrane oxygenation as a bridge to allogeneic hematopoietic stem cell transplantation. Intensive Care Med. 2014;40(12):1971-2.
Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31:2765-2772.
Yang SH, Teng HW, Hong YC, Liu CY, Yu YB, Yang CF, Gau JP, Liu JH, Chang TJ, Yen JJ, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT*. International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents. Ann Hematol 2012; 91:93-102.
Hsiao LT*, Yang CF, Yang SH, Gau JP, Yu YB, Hong YC, Liu CY, Liu JH, Chen PM, Chiou TJ, Tzeng CH. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma. Eur J Haematol 2012; 88:159-166.
Chou YS, Yang CF, Chen HS, Yang SH, Yu YB, Hong YC, Liu CY, Gau JP, Liu JH, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT*. Pre-existing diabetes mellitus in patients with multiple myeloma. Eur J Haematol 2012; 89:320-327.
Hu YH, Hsiao LT*, Yang CF, Chiou TJ, Liu JH, Gau JP, Yen CC, Chou TY, Hsu WH, Chen PM, Tzeng CH. Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin's lymphoma: the single-institute experience in Taiwan. Ann Hematol. 2009;88(9):839-46.
Chen MH, Hsiao LT*, Chiou TJ, Liu JH, Gau JP, Teng HW, Wang WS, Chao TC, Yen CC, Chen PM. High prevalence of occult hepatitis B virus infectionin patients with B cell non Hodgkin lymphoma, Ann Hematol. 2008; 87(6): 475-80.
Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, Yang MH, Tzeng CH, Chen PM. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12(1):84-94.
Hsiao LT, Lin JT, Yu IT, Chiou TJ, Liu JH, Yen CC, Wang WS, Chen PM. High serum hepatocyte growth factor level in patients with non Hodgkin lymphoma. Eur J Haematol. 2003;70(5):282-9.